Evidence map›Paper›PMID 40427042›Full record

ArticleBiomedicines2025

Targeting Aggressive Prostate Carcinoma Cells with Mesothelin-CAR-T Cells.

Apolline de Testas de Folmont, Angèle Fauvel, Francis Vacherot, Pascale Soyeux, Abdérémane Abdou, Salem Chouaib, Stéphane Terry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Apolline de Testas de FolmontINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, University Paris-Saclay, 94805 Villejuif, France.ORCID 0009-0009-6460-9046
Angèle FauvelINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, University Paris-Saclay, 94805 Villejuif, France.
Francis VacherotTRePCa, Université Paris Est Créteil, 94010 Creteil, France.
Pascale SoyeuxTRePCa, Université Paris Est Créteil, 94010 Creteil, France.
Abdérémane AbdouINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, University Paris-Saclay, 94805 Villejuif, France.
Salem ChouaibINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, University Paris-Saclay, 94805 Villejuif, France.
Stéphane TerryINSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, University Paris-Saclay, 94805 Villejuif, France.ORCID 0000-0003-3089-7886

Funding

ARTP (Association pour la Recherche sur les Tumeurs de la Prostate) do not apply
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adoptive cell immunotherapyaggressiveCAR-Tcell-mediated cytotoxicityepithelial–mesenchymal plasticityhypoxiamesothelinmetastatic cancerprostate cancerT cell

Identifiers

PMID40427042
PMCPMC12109071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.